Credit Suisse’s Kiora Pharmaceuticals KPRX Stock Holding History

Credit Suisse’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-28	Closed	-$23K	–	4602
2021 Q3	$23K	Buy	+28	New	+$23.8K	﹤0.01%	4364
2018 Q3	–	Sell	-4	Closed	-$12K	–	3891
2018 Q2	$12K	Sell	4 -1	-20%	-$2.82K	﹤0.01%	3935
2018 Q1	$10K	Buy	5 +1	+25%	+$4.32K	﹤0.01%	3938
2017 Q4	$21K	Sell	4 -2	-33%	-$12.4K	﹤0.01%	3940
2017 Q3	$35K	Buy	+6	New	+$38.2K	﹤0.01%	4147

Other funds holding KPRX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Credit Suisse's KPRX Position: Q4 2021 in Review

Credit Suisse sold out of Kiora Pharmaceuticals (KPRX) in Q4 2021, closing a stake of 28 shares — an estimated $23K sold.

Credit Suisse first reported a position in KPRX in Q3 2017 and held it in 5 quarters. The position peaked at $35K in Q3 2017. 11 funds tracked by Wall St. Rank hold KPRX as of Q4 2021.

Credit Suisse reported no remaining Kiora Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Credit Suisse sold 28 Kiora Pharmaceuticals shares in Q4 2021, an estimated $23K.
Credit Suisse first reported a position in Kiora Pharmaceuticals in Q3 2017 and held it in 5 quarters.
Credit Suisse's Kiora Pharmaceuticals position peaked at $35K in Q3 2017.
11 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2021.

Based on Credit Suisse's 13F filing for Q4 2021, filed 14 Feb 2022.